

HIV DART 2010
Scientific Program

Wednesday, December 8, 2010

- 8:00 **Opening Remarks**
Raymond F. Schinazi *Emory University/VA Medical Center, USA*
- 8:10 **Presentation of Gertrude Elion Distinguished Lecturer Award**
Robert Murphy *Northwestern University, USA*
Carlos del Rio *Emory University/Grady Memorial Hospital, USA*
- 8:20 **Gertrude Elion Distinguished Lecturer Award Lecture**
Persistence, Resistance, Diversity: Insights into the HIV-host Interaction
John Coffin *Tufts University, USA*
- Reservoirs, Persistence and Eradication**
- Chairs: Steven Deeks *University of California, USA*
 Daria Hazuda *Merck & Co., Inc, USA*
- 9:05 **State of the Art Lecture**
Tackling HIV Latency
Douglas Richman *University of California, San Diego/VA Medical Center, USA*
- 9:35 HIV-1 Utilizes the CXCR4 Chemokine Receptor to Infect Multipotent Hematopoietic Stem and Progenitor Cells
Kathleen Collins *University of Michigan, USA*
- 9:55 Prospects for HIV Eradication
Sharon Lewin *Alfred Hospital, Australia*
- 10:15 – 10:30 Panel Discussion**
- 10:30 – 10:45 Break**
- Immunotherapies**
- Chairs: John Moore *Weill Cornell Medical College, USA*
 Ila Singh *University of Utah, USA*
- 10:45 The PD-1 Inhibitory Co-signaling Pathway in HIV Infection and the Potential for Therapeutic Intervention
Daniel Kaufmann *Harvard University, USA*

11:05 Lentiviral Vectors as HIV Vaccine Candidates: A Highly Immunogenic Lentiviral Vaccine Provides Control of Viral Load, Preservation of the CD4 Compartment, and Survival Advantage Post-SIV Challenge
Franck Lemiale *VIRxSYS Corporation, USA*

11:25 – 11:40 Panel Discussion

Oral Abstract Session I

Chairs: Carlos del Rio *Emory University/Grady Memorial Hospital, USA*
 Sharon Lewin *Alfred Hospital, Australia*

11:40 DermaVir Therapeutic HIV Vaccine: Phase I and II Clinical Data in ARV Treated and Naïve HIV+ Subjects
Julianna Lisziewicz *Genetic Immunity, Hungary*

11:55 The Preclinical and Clinical Chemokine Receptor 2 (CCR2) Activity of TBR 652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection
Richard Ogden *Tobira Therapeutics, Inc., USA*

12:05 Development of a Cellular Immunotherapy for ART Naïve Patients for the Purpose of Delaying or Preventing Initiation of ART
Charles Nicolette *Argos Therapeutics, Inc., USA*

12:15 AIC246, a Potent Novel, Well Tolerated Non-Nucleosidic Compound Against Human Cytomegalovirus (HCMV) with Resistance Breaking Potential
Helga Rübsamen-Schaeff *AiCuris, Germany*

12:30 Lunch

14:00 – 16:00 Free Afternoon

16:00 – 18:00 Poster Session

Viral Hepatitis Co-infection and Other HIV Co-morbidities

Chairs: Nicolas Sluis-Cremer *University of Pittsburgh, USA*
 David Cooper *University of New South Wales National Centre in HIV Epidemiology & Clinical Research, Australia*

18:00 **State of the Art Lecture**
Liver Disease and Therapy of Hepatitis B Virus Infection in HIV Infected Persons
William Mason *Fox Chase Cancer Center, USA*

18:30 Co-infection with Hepatitis B
Marion Peters *University of California, San Francisco, USA*

- 18:50 Acute Hepatitis C in HIV: Lessons Learned
Jürgen Rockstroh *University of Bonn, Germany*
- 19:10 Malignancies in HIV: A Growing Problem
Ronald Mitsuyasu *University of California, Los Angeles, USA*

19:30 – 19:45 Panel Discussion

Thursday, December 9, 2010

Antiretroviral Targets

- Chairs: Raymond F. Schinazi *Emory University/VA Medical Center, USA*
Hiroaki Mitsuya *Kumamoto University School of Medicine, Japan and National Cancer Institute, USA*

- 8:00 Presentation of David Barry DART Achievement Award
Raymond F. Schinazi *Emory University/VA Medical Center, USA*
The Award will be given to Dr. Kempf by Mrs. Gracia Barry

- 8:10 **David Barry DART Achievement Award Lecture**
Pharmacokinetic Boosting: A Paradigm Shift in Antiviral Therapy
Dale Kempf *Abbott Laboratories, USA*

- 8:55 Discovery of Novel Inhibitors of HIV-1 Reverse Transcriptase by Crystallographic Fragment Screening
Eddy Arnold *Rutgers University, USA*

- 9:15 Small Molecule Inhibition of Human Immunodeficiency Virus Type 1 Infection by Virus Capsid Destabilization
Christopher Aiken *Vanderbilt University, USA*

- 9:35 HIV Gag and PR: Partners in Resistance to Protease and Maturation Inhibitors
Monique Nijhuis *University Medical Center Utrecht, the Netherlands*

9:55 – 10:10 Panel Discussion

10:10 – 10:25 Break

Treatment Strategies in Developing Countries

Chairs: Luis Soto-Ramirez *Instituto Nacional de Ciencias Medicas y Nutricion, Mexico*
Dennis Liotta *Emory University, USA*

10:25 Infant HAART in Resource Limited Countries
Annelies Van Rie *University of North Carolina Chapel Hill, USA*

10:45 Differences between HIV Subtypes in Development of Drug Resistance: The Clustering of Transmitted Resistance
Mark Wainberg *McGill AIDS Center, Canada*

11:05 The Impact of CMV-associated Inflammation on HIV Disease Outcomes
Steven Deeks *University of California, San Francisco, USA*

11:25 – 11:40 Panel Discussion

11:40 **Special Lecture**
Implications of Lymphatic Tissue Pathology for Early Initiation of ART
Ashley Haase *University of Minnesota, USA*

Oral Abstract Session II

Chairs: Leonid Margolis *National Institutes of Health, USA*
Kathleen Collins *University of Michigan, USA*

12:10 Complementary Strategies to Block Translocation of HIV-1 Reverse Transcriptase
Matthias Götze *McGill University, Canada*

12:20 Structure-guided Development of Antiviral Agents for Treating HIV-1 Infection and AIDS: Non-Peptidyl HIV-1 Protease Dimerization Inhibitors (PDIs)
Hiroaki Mitsuya *Kumamoto University School of Medicine, Japan and National Cancer Institute, USA*

12:30 Homing Endonucleases for the Targeted Disruption of Integrated HIV
Keith Jerome *Fred Hutchinson Cancer Research Center, and University of Washington, USA*

12:40 Lunch

14:00 – 16:30 Free Afternoon

Poster Discussions

- Chair: Raymond Schinazi *Emory University/VA Medical Center, USA*
- 16:30 Poster Discussion I (Pre-clinical)
Brendan Larder *RDI, UK*
- 17:00 Poster Discussion II (Clinical)
Richard Pollard *University of California, Davis Medical Center, USA*

Inflammation, Pharmacology, Toxicology and Drug Metabolism

- Chairs: Monique Nijhuis *University Medical Center Utrecht, the Netherlands*
William Mason *Fox Chase Cancer Center, USA*
- 17:30 **State of the Art Lecture**
Lipodystrophy and Metabolic Toxicity of Antiretroviral Therapy
David Cooper *University of New South Wales National Centre in HIV Epidemiology & Clinical Research, Australia*
- 18:00 Chronic Inflammation and Medical Complications in HIV
David Shepp *Hofstra University School of Medicine, North Shore University Hospital, USA*
- 18:25 HIV, Inflammation, and Cardiovascular Disease
Laurence Sperling *Emory University School of Medicine, USA*
- 18:50 **Oral Abstract**
12 Week Analysis of the SENSE Trial: Etravirine versus Efavirenz in Treatment-naïve Patients
Mark Nelson *Chelsea and Westminster Hospital, UK*

19:00 – 19:15 Panel Discussion

20:00 Gala Party

Friday, December 10, 2010

Preventing Transmission: Microbicides and Other Approaches

- Chairs: Douglas Richman *University of California, San Diego/VA Medical Center, USA*
Tom North *Emory University, USA*
- 8:00 **State of the Art Lecture**
Treatment as Prevention: Five Year Experience in British Columbia, Canada
Julio Montaner *BC Centre for Excellence in HIV/AIDS, Canada*

8:30 CCR5 Inhibitors as Vaginal Microbicides
John Moore *Weill Cornell Medical College, USA*

8:50 Pre-exposure Prophylaxis
James Rooney *Gilead Sciences, USA*

9:05 A Pill a Day to Keep HIV Away
Robert Grant *Gladstone/UCSF, USA*

9:20 Sex is Messy
Davey Smith *University of California, San Diego, USA*

9:40 Panel Discussion

9:55 Break

Novel Monitoring and Diagnostic Approaches

Chairs: Marion Peters *University of California, San Francisco, USA*
Robert Murphy *Northwestern University, USA*

10:10 Predicting HIV Response to Antiretroviral Therapy
Daniel Kuritzkes *Brigham and Women's Hospital, USA*

10:35 Special Lecture

-11:05 Emerging Retroviruses: XMRV: The Link to Prostate Cancer and Chronic Fatigue Syndrome
Ila Singh *University of Utah, USA*

Oral Abstract Session III

Chairs: Robert Murphy *Northwestern University, USA*
David Shepp *Hofstra University School of Medicine, North Shore University Hospital, USA*

11:05 CMX157 (Hexadecyloxypropyl Tenofovir), a Clinical Stage Antiretroviral with Activity against HIV and XMRV
Randall Lanier *Chimerix Inc., USA*

11:15 Anti-HIV Effect In Vitro of Human Milk Glycosaminoglycans
Monica Viveros-Rogel *Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico*

11:25 What Should be the Primary Virological Endpoint in Clinical Trials of Antiretroviral Efficacy?
Richard Harrigan *BC Centre for Excellence in HIV/AIDS, Canada*

- 11:35 Pooled Week 48 Efficacy and Safety Results from ECHO and THRIVE, Two Double-blind, Randomized, Phase III Trials Comparing TMC278 versus Efavirenz in Treatment-naïve, HIV-1-infected Patients
Katia Boven *Tibotec Inc., USA*
- 11:45 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl] Nucleosides: A New Mechanism of Inhibition of HIV Replication
Karl Hostetler *University of California San Diego, USA*
- 11:55 Cellular Pharmacology and Antiviral Potency of Antiretroviral Agents in Primary Human Macrophages and Lymphocytes: Implication for Eradication
Christina Gavegnano *Emory University/VA Medical Center, USA*
- 12:05 Closing Remarks**
Raymond F. Schinazi *Emory University/VA Medical Center, USA*
- 12:15 Lunch on your own**